Anthony Quinn, Director at Aeglea BioTherapeutics, Inc. (AGLE), bought 10,000 shares at $10.00 ($100K) on 2016-04-12, disclosed to the SEC on 2016-04-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| GEVA | SELL | 2015-04-17 | $1.1M | — | Filing → |
| GEVA | SELL | 2015-04-08 | $2.8M | — | Filing → |
| GEVA | SELL | 2014-04-03 | $1.7M | — | Filing → |